Optimizing clinical development strategy for the rapidly evolving I-O field

IMMUNO-ONCOLOGY INSIGHTS

Optimizing clinical development strategy for the rapidly evolving I-O field

March 2022
Optimizing clinical development strategy for the rapidly evolving I-O field
Download PDF

Foreword

Spotlight on optimizing clinical development strategy

Spotlight on optimizing clinical development strategy

Jill O'Donnell-Tormey
29 March 2022
Read

Commentary

Cancer immunotherapy & clinical trial design: issues & practice

Cancer immunotherapy & clinical trial design: issues & practice

Janet E Dancey, MD, FRCPC
30 March 2022
Read
Beyond PD-L1: novel predictive biomarkers for adjuvant immunotherapy in renal cell and urothelial carcinoma

Beyond PD-L1: novel predictive biomarkers for adjuvant immunotherapy in renal cell and urothelial carcinoma

J Brown, A Rajkumar, J Garcia
27 March 2022
Read
The cutting edge: leveraging pre-surgical immunotherapy trials to understand therapeutic mechanisms

The cutting edge: leveraging pre-surgical immunotherapy trials to understand therapeutic mechanisms

B Fitzgerald, M Galsky, T Marron
15 March 2022
Read

Interview

Expediting drug development & targeting early-stage disease: how is clinical trial design in immuno-oncology evolving?

Expediting drug development & targeting early-stage disease: how is clinical trial design in immuno-oncology evolving?

Patrick Forde
27 March 2022
Read
Immunotherapy questions in melanoma

Immunotherapy questions in melanoma

Michael Postow
10 February 2022
Read

Review

Expanding the reach of immuno-oncology: considerations for optimizing treatment of solid malignancies in the future

Expanding the reach of immuno-oncology: considerations for optimizing treatment of solid malignancies in the future

Luke Mantle, Samuel D Saibil
15 March 2022
Read

Viewpoint

Critical collaboration: Efforts to expand clinical trial eligibility

Critical collaboration: Efforts to expand clinical trial eligibility

Jeff Allen
28 February 2022
Read